Liver cancer stem cell niche response type step-by-step targeting liposome and application thereof
The invention discloses a liver cancer stem cell niche response type step-by-step targeting liposome and application thereof, and belongs to the field of pharmaceutical preparations. The liposome comprises a base material, a drug entrapped by the base material and a targeting molecule targeting liver cancer related fibroblasts and stem cells, and the base material comprises egg yolk lecithin, cholesterol, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and distearoyl phosphatidyl ethanolamine-polyethylene glycol-maleimide. The drug comprises a chemotherapeutic drug and an inhibitor for inhibiting the dryness of the stem cells, and the targeting molecule comprises DSPE-PEG2000-CAP-PEG2000-UAMC1110 and a CD133 aptamer. The liposome is used for efficiently delivering a chemotherapeutic drug doxorubicin hydrochloride and a liver cancer stem cell stemness inhibitor XAV-939, so that damage to normal tissues and normal stem cells is relieved, chemical drug resistance is improved, metastasis and relapse are inhibited, and the liposome has important theoretical significance and clinical significance..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 02. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
KONG LIANG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-02, Last update posted on www.tib.eu: 2024-03-25, Last updated: 2024-03-29 |
|---|
| Patentnummer: |
CN117482249 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA002831260 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA002831260 | ||
| 003 | DE-627 | ||
| 005 | 20240329160939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA002831260 | ||
| 035 | |a (EPA)CN117482249 | ||
| 035 | |a (EPA)89674492 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a KONG LIANG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Liver cancer stem cell niche response type step-by-step targeting liposome and application thereof |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-02, Last update posted on www.tib.eu: 2024-03-25, Last updated: 2024-03-29 | ||
| 520 | |a The invention discloses a liver cancer stem cell niche response type step-by-step targeting liposome and application thereof, and belongs to the field of pharmaceutical preparations. The liposome comprises a base material, a drug entrapped by the base material and a targeting molecule targeting liver cancer related fibroblasts and stem cells, and the base material comprises egg yolk lecithin, cholesterol, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and distearoyl phosphatidyl ethanolamine-polyethylene glycol-maleimide. The drug comprises a chemotherapeutic drug and an inhibitor for inhibiting the dryness of the stem cells, and the targeting molecule comprises DSPE-PEG2000-CAP-PEG2000-UAMC1110 and a CD133 aptamer. The liposome is used for efficiently delivering a chemotherapeutic drug doxorubicin hydrochloride and a liver cancer stem cell stemness inhibitor XAV-939, so that damage to normal tissues and normal stem cells is relieved, chemical drug resistance is improved, metastasis and relapse are inhibited, and the liposome has important theoretical significance and clinical significance. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LI XUETAO |4 aut | |
| 700 | 0 | |a YU YANG |4 aut | |
| 700 | 0 | |a LIU YANG |4 aut | |
| 700 | 0 | |a ZANG JUAN |4 aut | |
| 700 | 0 | |a GUO RUIBO |4 aut | |
| 700 | 0 | |a ZHANG LU |4 aut | |
| 700 | 0 | |a LI SHUTONG |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 02. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:02 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89674492/publication/CN117482249A1?q=CN117482249 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 02 |c 02 | ||